Antisense Oligonucleotide-Mediated Downregulation of IGFBPs Enhances IGF-1 Signaling

Overview

Journal J Neuromuscul Dis

Publisher Sage Publications

Specialty Neurology

Date 2024 Jan 8

PMID 38189760

Authors

Alper Yavas

Maaike van Putten

Annemieke Aartsma-Rus

Affiliations

Soon will be listed here.

Abstract

Insulin-like growth factor-1 (IGF-1) has been considered as a therapeutic agent for muscle wasting conditions including Duchenne muscular dystrophy as it stimulates muscle regeneration, growth and function. Several preclinical and clinical studies have been conducted to show the therapeutic potential of IGF-1, however, delivery issues, short half-life and isoform complexity have impose challenges. Antisense oligonucleotides (AONs) are able to downregulate target proteins by interfering with their transcripts. Here, we investigated the feasibility of enhancing IGF-1 signaling by downregulation of IGF-binding proteins. We observed that out of frame exon skipping of Igfbp1 and Igfbp3 downregulated their protein expression, which increased Akt phosphorylation on the downstream IGF-1 signaling in vitro. 3'RNA sequencing analysis revealed the related transcriptome in C2C12 cells in response to IGFBP3 downregulation. The AONs did however not induce any exon skipping or protein knockdown in mdx mice after 6 weeks of systemic treatment. We conclude that IGFBP downregulation could be a good strategy to increase IGF-1 signaling but alternative tools are needed for efficient delivery and knockdown in vivo.

Citing Articles

Oligonucleotide therapeutics in sports? An antidoping perspective.

Parr M, Keiler A Arch Pharm (Weinheim). 2024; 358(1):e2400404.

PMID: 39449227 PMC: 11704058. DOI: 10.1002/ardp.202400404.

References

Gehrig S, van der Poel C, Hoeflich A, Naim T, Lynch G, Metzger F . Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy. Growth Horm IGF Res. 2012; 22(2):69-75. DOI: 10.1016/j.ghir.2012.02.004. View

Stilling F, Wallenius S, Michaelsson K, Dalgard C, Brismar K, Wolk A . High insulin-like growth factor-binding protein-1 (IGFBP-1) is associated with low relative muscle mass in older women. Metabolism. 2017; 73:36-42. DOI: 10.1016/j.metabol.2017.04.013. View

Ji G, Sun S, Wu H, Chen X, Cui H, Tang J . Effect of AAV9-hIGF-1 on inflammatory reaction in mdx mice and its mechanism. Am J Transl Res. 2020; 12(8):4488-4497. PMC: 7476146. View

Nguyen D, Li Calzi S, Shaw L, Kielczewski J, Korah H, Grant M . An ocular view of the IGF-IGFBP system. Growth Horm IGF Res. 2013; 23(3):45-52. PMC: 3833084. DOI: 10.1016/j.ghir.2013.03.001. View

Deyhle M, Hafen P, Parmley J, Preece C, Robison M, Sorensen J . CXCL10 increases in human skeletal muscle following damage but is not necessary for muscle regeneration. Physiol Rep. 2018; 6(8):e13689. PMC: 5917067. DOI: 10.14814/phy2.13689. View

Kemaladewi D, Hoogaars W, van Heiningen S, Terlouw S, de Gorter D, den Dunnen J . Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics. 2011; 4:36. PMC: 3107769. DOI: 10.1186/1755-8794-4-36. View

Springer A, Dowdy S . GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. Nucleic Acid Ther. 2018; 28(3):109-118. PMC: 5994659. DOI: 10.1089/nat.2018.0736. View

Matsuo M . Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy. JMA J. 2021; 4(3):232-240. PMC: 8355726. DOI: 10.31662/jmaj.2021-0019. View

Fairclough R, Wood M, Davies K . Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013; 14(6):373-8. DOI: 10.1038/nrg3460. View

10.

Geary R, Norris D, Yu R, Bennett C . Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015; 87:46-51. DOI: 10.1016/j.addr.2015.01.008. View

11.

McCarthy D, Chen Y, Smyth G . Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 2012; 40(10):4288-97. PMC: 3378882. DOI: 10.1093/nar/gks042. View

12.

Prakash T, Graham M, Yu J, Carty R, Low A, Chappell A . Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014; 42(13):8796-807. PMC: 4117763. DOI: 10.1093/nar/gku531. View

13.

Varma Shrivastav S, Bhardwaj A, Pathak K, Shrivastav A . Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3): Unraveling the Role in Mediating IGF-Independent Effects Within the Cell. Front Cell Dev Biol. 2020; 8:286. PMC: 7232603. DOI: 10.3389/fcell.2020.00286. View

14.

Barton E, Morris L, Musaro A, Rosenthal N, Sweeney H . Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol. 2002; 157(1):137-48. PMC: 2173262. DOI: 10.1083/jcb.200108071. View

15.

Ascenzi F, Barberi L, Dobrowolny G, Villa Nova Bacurau A, Nicoletti C, Rizzuto E . Effects of IGF-1 isoforms on muscle growth and sarcopenia. Aging Cell. 2019; 18(3):e12954. PMC: 6516183. DOI: 10.1111/acel.12954. View

16.

Bach L . IGF-binding proteins. J Mol Endocrinol. 2017; 61(1):T11-T28. DOI: 10.1530/JME-17-0254. View

17.

Eckardt L, Harzer W . Facial structure and functional findings in patients with progressive muscular dystrophy (Duchenne). Am J Orthod Dentofacial Orthop. 1996; 110(2):185-90. DOI: 10.1016/s0889-5406(96)70107-5. View

18.

Schoch K, Miller T . Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases. Neuron. 2017; 94(6):1056-1070. PMC: 5821515. DOI: 10.1016/j.neuron.2017.04.010. View

19.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

20.

Hagstrom H, Stal P, Hultcrantz R, Brismar K, Ansurudeen I . IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD - a pilot study. Scand J Gastroenterol. 2017; 52(12):1427-1434. DOI: 10.1080/00365521.2017.1379556. View